Anti-Cancer Medicines Availability Study
Study objectives: to provide European health authorities with data on the availability of licensed anti-neoplastic medicines across Europe
This ESMO study is conducted under the auspices of the ESMO Emerging Countries Committee in collaboration with the World Health Organization, the Kings College London Institute of Cancer Policy, the Union for International Cancer Control, and the European Society of Oncology Pharmacy (liaising with the European Association of Hospital Pharmacy).
The goals of this study are:
- to provide European health authorities with data on the availability of licensed anti-neoplastic medicines across Europe
- to report on the actual availability of anti-neoplastic medicines to patients when they are prescribed and when patients can afford them
- to provide data so that the European Union and the European Medicines Agency can decide how to best address and resolve the challenges identified
- Note: the study did not include the clinical benefit of the cancer medicines surveyed
The study data was presented at the ESMO 2014 Congress in Madrid. The peer review period was from 13 November 2014 until 6 February 2015. A publication in ESMO's scientific journal Annals of Oncology is due in 2015.